This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Sibutramine and cholesterol

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

There is evidence that treatment with sibutramine can lead to significant improvements in lipid profile and insulin resistance (1).

  • a 2 year study in uncomplicated obese individuals showed that patients who lost 5% of weight with an initial 6 months of sibutramine 10mg/day, went on to achieve an average weight loss of 10.2 kg (versus 4.7kg with placebo) after a further 18 months treatment

Lipid findings:

  • HDL cholesterol increased by approximately 20% in the sibutramine treated group versus approximately 10% in the placebo group
  • triglycerides reduced by 20% in the sibutramine-treated group versus 4% in the placebo group
  • reduction in total cholesterol: HDL ratio of 13% in the sibutramine-treated group


  • (1) James WPT et al (2000). Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet, 356, 2119-25.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.